Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists.

Sidduri A, Budd DC, Fuentes ME, Lambros T, Ren Y, Roongta V, Schoenfeld RC, Gillespie P, Stevenson CS, Truitt T, Qian Y.

Bioorg Med Chem Lett. 2014 Sep 15;24(18):4450-4454. doi: 10.1016/j.bmcl.2014.08.001. Epub 2014 Aug 8.

PMID:
25155385
2.

Metabolic activation of the indoloquinazoline alkaloids evodiamine and rutaecarpine by human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.

Wen B, Roongta V, Liu L, Moore DJ.

Drug Metab Dispos. 2014 Jun;42(6):1044-54. doi: 10.1124/dmd.114.057414. Epub 2014 Apr 2.

PMID:
24696463
3.

A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study.

Furlong MT, Savant I, Yuan M, Scott L, Mylott W, Mariannino T, Kadiyala P, Roongta V, Arnold ME.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:36-41. doi: 10.1016/j.jchromb.2013.02.031. Epub 2013 Mar 1.

PMID:
23542721
4.

Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.

Yang Z, Vakkalagadda B, Shen G, Ahlers CM, Has T, Christopher LJ, Kurland JF, Roongta V, Masson E, Zhang S.

J Clin Pharmacol. 2013 Feb;53(2):217-27. doi: 10.1177/0091270012439208.

PMID:
23436267
5.

Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects.

Vakkalagadda B, Park JS, Ahlers CM, Dorizio S, Has T, Roongta V, Heller KN, Derbin GM, Zhang S.

J Clin Pharmacol. 2012 Sep;52(9):1350-6. doi: 10.1177/0091270011417826. Epub 2011 Oct 26.

PMID:
22031621
6.

Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine.

Hong H, Caceres-Cortes J, Su H, Huang X, Roongta V, Bonacorsi S Jr, Hong Y, Tian Y, Iyer RA, Humphreys WG, Christopher LJ.

Chem Res Toxicol. 2011 Jan 14;24(1):125-34. doi: 10.1021/tx100337s. Epub 2010 Nov 16.

PMID:
21080678
7.

15N chemical shifts of a series of isatin oxime ethers and their corresponding nitrone isomers.

Liu X, Huang XS, Sin N, Venables BL, Roongta V.

Magn Reson Chem. 2010 Nov;48(11):873-6. doi: 10.1002/mrc.2680.

PMID:
20818803
8.

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.

Christopher LJ, Hong H, Vakkalagadda BJ, Clemens PL, Su H, Roongta V, Allentoff A, Sun H, Heller K, Harbison CT, Iyer RA, Humphreys WG, Wong T, Zhang S.

Drug Metab Dispos. 2010 Nov;38(11):2049-59. doi: 10.1124/dmd.110.034850. Epub 2010 Jul 28.

PMID:
20668249
9.

Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.

Hong H, Su H, Sun H, Allentoff A, Ekhato IV, Chando T, Caceres-Cortes J, Roongta V, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2010 Jul;38(7):1189-201. doi: 10.1124/dmd.110.032755. Epub 2010 Apr 2.

PMID:
20363952
10.

Disposition of [1'-(14)C]stavudine after oral administration to humans.

Zhou L, Kaul S, Liu-Kreyche P, Tran SB, Espina RR, Warrack BM, Roongta VA, Iyer RA.

Drug Metab Dispos. 2010 Apr;38(4):655-66. doi: 10.1124/dmd.109.030239. Epub 2010 Jan 6.

PMID:
20053818
11.

Observation of O-H...N scalar coupling across a hydrogen bond in nocathiacin I.

Huang XS, Liu X, Constantine KL, Leet JE, Roongta V.

Magn Reson Chem. 2007 Jun;45(6):447-50.

PMID:
17431856
12.

In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor.

Zhang D, Hanson R, Roongta V, Dischino DD, Gao Q, Sloan CP, Polson C, Keavy D, Zheng M, Mitroka J, Yeola S.

Curr Drug Metab. 2006 Dec;7(8):883-96.

PMID:
17168689
13.

Metabolomic analysis using optimized NMR and statistical methods.

AranĂ­bar N, Ott KH, Roongta V, Mueller L.

Anal Biochem. 2006 Aug 1;355(1):62-70. Epub 2006 May 22.

PMID:
16762305
14.

Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.

Fura A, Shu YZ, Zhu M, Hanson RL, Roongta V, Humphreys WG.

J Med Chem. 2004 Aug 26;47(18):4339-51. Review. No abstract available.

PMID:
15317447
15.

Amide N-glucuronidation of MaxiPost catalyzed by UDP-glucuronosyltransferase 2B7 in humans.

Zhang D, Zhao W, Roongta VA, Mitroka JG, Klunk LJ, Zhu M.

Drug Metab Dispos. 2004 May;32(5):545-51.

PMID:
15100177
16.

Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats.

Zhang D, Ogan M, Gedamke R, Roongta V, Dai R, Zhu M, Rinehart JK, Klunk L, Mitroka J.

Drug Metab Dispos. 2003 Jul;31(7):837-45.

PMID:
12814959
17.

Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans.

Iyer RA, Mitroka J, Malhotra B, Bonacorsi S Jr, Waller SC, Rinehart JK, Roongta VA, Kripalani K.

Drug Metab Dispos. 2001 Jan;29(1):60-9.

PMID:
11124231
18.

Eosinophil peroxidase oxidation of thiocyanate. Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system.

Arlandson M, Decker T, Roongta VA, Bonilla L, Mayo KH, MacPherson JC, Hazen SL, Slungaard A.

J Biol Chem. 2001 Jan 5;276(1):215-24.

19.

NMR structure and dynamics of monomeric neutrophil-activating peptide 2.

Young H, Roongta V, Daly TJ, Mayo KH.

Biochem J. 1999 Mar 15;338 ( Pt 3):591-8.

20.

Ionization and solubilization of 4 alkyl benzoic acids and 4 alkyl anilines in sodium taurodeoxycholate solutions.

Wiedmann TS, Kvanbeck K, Han CH, Roongta V.

Pharm Res. 1997 Nov;14(11):1574-82.

PMID:
9434277
21.

NMR structure of a de novo designed, peptide 33mer with two distinct, compact beta-sheet folds.

Ilyina E, Roongta V, Mayo KH.

Biochemistry. 1997 Apr 29;36(17):5245-50.

PMID:
9136886
22.

A pulsed-field gradient NMR study of bovine pancreatic trypsin inhibitor self-association.

Ilyina E, Roongta V, Pan H, Woodward C, Mayo KH.

Biochemistry. 1997 Mar 18;36(11):3383-8.

PMID:
9116018
23.

Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding.

Mayo KH, Ilyina E, Roongta V, Dundas M, Joseph J, Lai CK, Maione T, Daly TJ.

Biochem J. 1995 Dec 1;312 ( Pt 2):357-65.

24.

NMR solution structure of the 32-kDa platelet factor 4 ELR-motif N-terminal chimera: a symmetric tetramer.

Mayo KH, Roongta V, Ilyina E, Milius R, Barker S, Quinlan C, La Rosa G, Daly TJ.

Biochemistry. 1995 Sep 12;34(36):11399-409.

PMID:
7547867
26.
27.

Sequence-dependent variations in the 31P NMR spectra and backbone torsional angles of wild-type and mutant Lac operator fragments.

Schroeder SA, Roongta V, Fu JM, Jones CR, Gorenstein DG.

Biochemistry. 1989 Oct 17;28(21):8292-303.

PMID:
2605186
28.

Solution conformation of a synthetic fragment of human pituitary growth hormone. Two-dimensional NMR of an alpha-helical dimer.

Roongta V, Powers R, Jones C, Beakage MJ, Shields JE, Gorenstein DG.

Biochemistry. 1989 Feb 7;28(3):1048-54.

PMID:
2713357

Supplemental Content

Loading ...
Support Center